I-Mab (NASDAQ: IMAB), a US-based biotechnology firm focused on innovative cancer immunotherapies, announced on Wednesday that it will present optimised dose estimation data for its bispecific antibody givastomig (TJ033721/ABL111) during a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) conference on 9 November 2024.

The session will take place in Houston, Texas, at the George R. Brown Convention Center.

Givastomig, which targets Claudin18.2 (CLDN18.2)-positive tumour cells and activates T cells through the 4-1BB pathway in the tumour microenvironment, has shown strong anti-tumour efficacy with reduced immunotoxicity. It received FDA Orphan Drug Designation in 2022 for gastric cancer. A Phase 1b study is ongoing to assess its combination with nivolumab and chemotherapy for treatment-naïve gastric cancer patients.

I-Mab leads the global development of givastomig with partner ABL Bio, sharing worldwide rights outside of China and South Korea.